natgillin/translations-raw huggingface dataset:
Four studies looked at the treatment of the disorder by measuring the reduction in symptoms after nine to 10 weeks. 
V štirih študijah so proučevali zdravljenje bolezni, tako da so merili zmanjšanje simptomov po devetih do desetih tednih.
It works by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord. 
Deluje tako, da živčnima prenašalcema 5-hidroksitriptaminu (imenovanemu tudi serotonin) in noradrenalinu preprečuje ponoven prevzem v živčne celice v možganih in hrbtenjači.
Most of these are mild or moderate, starting early in treatment and getting milder as treatment continues. 
Ti neželeni učinki so bili večinoma blagi do zmerni; nastopili so kmalu po začetku zdravljenja in so z nadaljevanjem zdravljenja postajali vse blažji.
Six of the studies looked at the treatment of depression and measured the change in symptoms over up to six months. 
V šestih študijah so proučevali zdravljenje depresivnih motenj in merili spremembe simptomov v obdobju, ki je trajalo do šest mesecev.
Duloxetine Lilly must not be used together with monoamine oxidase inhibitors (another group of antidepressants), fluvoxamine (another antidepressant), or ciprofloxacin or enoxacin (types of antibiotics). 
Zdravilo Duloxetine Lilly se ne sme uporabljati sočasno z zaviralci monoaminooksidaze (drugo skupino zdravil proti depresiji), fluvoksaminom (drugim zdravilom proti depresiji) ali ciprofloksacinom ali enoksacinom (vrstama antibiotikov).
By blocking their re-uptake, duloxetine increases the amount of these neurotransmitters in the spaces between these nerve cells, increasing the level of communication between the cells. 
Duloksetin z zaviranjem ponovnega prevzema navedenih živčnih prenašalcev povečuje njuno količino v prostorih med živčnimi celicami in s tem povečuje stopnjo komunikacije med celicami.
The company that makes Cymbalta has agreed that its scientific data can be used for Duloxetine Lilly (‘informed consent'). 
Družba, ki proizvaja zdravilo Cymbalta, se strinja, da se lahko znanstveni podatki o tem zdravilu uporabijo tudi za zdravilo Duloxetine Lilly („uporaba dokumentacije s soglasjem“).
What measures are being taken to ensure the safe and effective use of Duloxetine Lilly? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Duloxetine Lilly?
For generalised anxiety disorder, the recommended starting dose is 30 mg once a day, but the dose can be increased to 60, 90 or 120 mg depending on the patient's response. 
Pri generalizirani anksiozni motnji je priporočeni začetni odmerek 30 mg enkrat na dan, vendar se lahko glede na odziv bolnika odmerek poveča na 60, 90 ali 120 mg.
The dose of Duloxetine Lilly should be reduced gradually when stopping treatment. 
Odmerek zdravila Duloxetine Lilly je treba ob zaključku zdravljenja zmanjševati postopoma.
For major depression, the recommended dose of Duloxetine Lilly is 60 mg once a day. 
Pri velikih depresivnih motnjah je priporočeni odmerek zdravila Duloxetine Lilly 60 mg enkrat na dan.
The fifth study looked at how long it took for symptoms to return in 429 patients who had initially responded to Duloxetine Lilly. 
V peti študiji so preučevali, kako dolgo je trajalo, da so se pri 429 bolnikih, ki so se prvotno odzvali na zdravilo Duloxetine Lilly, simptomi ponovno pojavili.
The active substance in this medicine, duloxetine, is a serotonin-noradrenaline re-uptake inhibitor. 
Zdravilna učinkovina tega zdravila, duloksetin, je zaviralec ponovnega prevzema serotonina in noradrenalina.
For more information about treatment with Duloxetine Lilly, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Duloxetine Lilly preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Duloxetine Lilly, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Duloxetine Lilly in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
A risk management plan has been developed to ensure that Duloxetine Lilly is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Duloxetine Lilly je bil pripravljen načrt obvladovanja tveganj.
Duloxetine Lilly must also not be used in patients with reduced liver function or patients with severely reduced kidney function. 
Zdravilo Duloxetine Lilly se tudi ne sme uporabljati za zdravljenje bolnikov z oslabljenim delovanjem jeter in bolnikov s hudo oslabljenim delovanjem ledvic.
The other two studies looked at how long it took for symptoms to return in patients who had initially responded to Duloxetine Lilly, including 288 patients with a history of repeated episodes of depression for up to five years. 
Drugi dve študiji sta proučevali, kako dolgo je trajalo, da so se pri bolnikih, ki so se prvotno odzvali na zdravilo Duloxetine Lilly, ponovno pojavili simptomi, vključno pri 288 bolnikih, ki so v preteklosti že doživljali ponavljajoče se epizode depresije, pri čemer je to obdobje trajalo do pet let.
For diabetic neuropathic pain, the recommended dose is 60 mg per day but some patients may need a higher dose of 120 mg per day. 
Pri bolnikih z bolečino diabetične nevropatije je priporočeni odmerek 60 mg na dan, nekateri bolniki pa bodo morda potrebovali večji odmerek v višini 120 mg na dan.
Other information about Duloxetine Lilly 
Druge informacije o zdravilu Duloxetine Lilly
For practical information about using Duloxetine Lilly, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Duloxetine Lilly naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
In patients who respond to Duloxetine Lilly, treatment should continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past. 
Pri bolnikih, ki se odzovejo na zdravilo Duloxetine Lilly, bi naj zdravljenje potekalo več mesecev, da bi preprečili ponoven pojav bolezni, ali dlje, v kolikor so bolniki v preteklosti imeli ponavljajoča se obdobja depresije.
What are the risks associated with Duloxetine Lilly? 
Kakšna tveganja so povezana z zdravilom Duloxetine Lilly?
In patients who respond to Duloxetine Lilly, treatment should continue for several months, to prevent the disorder coming back. 
Pri bolnikih, ki se odzovejo na zdravilo Duloxetine Lilly, bi naj zdravljenje potekalo več mesecev, da bi preprečili ponoven pojav bolezni.
What benefits of Duloxetine Lilly have been shown in studies? 
Kakšne koristi je zdravilo Duloxetine Lilly izkazalo v študijah?
What is Duloxetine Lilly and what is it used for? 
Kaj je zdravilo Duloxetine Lilly in za kaj se uporablja?
In the two studies where the approved dose of Duloxetine Lilly was compared with placebo, Duloxetine Lilly was more effective. 
V dveh študijah, v katerih so odobreni odmerek zdravila Duloxetine Lilly primerjali s placebom, je bilo zdravilo Duloxetine Lilly učinkovitejše.
For generalised anxiety disorder, Duloxetine Lilly has been compared with placebo in five studies involving a total of 2,337 patients. 
Pri zdravljenju generalizirane anksiozne motnje so zdravilo Duloxetine Lilly primerjali s placebom v petih študijah, v katere je bilo skupaj vključenih 2 337 bolnikov.
For neuropathic pain, Duloxetine Lilly has been compared with placebo in two 12-week studies in 809 diabetic adults. 
Pri zdravljenju nevropatske bolečine so zdravilo Duloxetine Lilly primerjali s placebom v dveh študijah, ki sta trajali 12 tednov in v kateri je bilo vključenih 809 odraslih s sladkorno boleznijo.
For the full list of all side effects reported with Duloxetine Lilly, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Duloxetine Lilly, glejte navodilo za uporabo.
Why is Duloxetine Lilly approved? 
Zakaj je bilo zdravilo Duloxetine Lilly odobreno?
For major depression, Duloxetine Lilly has been compared with placebo (a dummy treatment) in eight main studies involving a total of 2,544 patients. 
Pri zdravljenju velikih depresivnih motenj so zdravilo Duloxetine Lilly primerjali s placebom (zdravilom brez zdravilne učinkovine) v osmih glavnih študijah, v katere je bilo skupaj vključenih 2 544 bolnikov.
Although the results of the depression studies varied, Duloxetine Lilly was more effective than placebo in four of the studies. 
Čeprav so se rezultati študij o zdravljenju depresivnih motenj razlikovali, je bilo zdravilo Duloxetine Lilly v štirih študijah učinkovitejše od placeba.
These studies showed that Duloxetine Lilly was more effective at reducing pain than placebo. 
Študiji sta pokazali, da je bilo zdravilo Duloxetine Lilly pri zmanjševanju bolečine učinkovitejše od placeba.
It also took longer for symptoms to return in patients taking Duloxetine Lilly than in those taking placebo. 
Prav tako je bil pri bolnikih, ki so jemali zdravilo Duloxetine Lilly, čas do ponovnega pojava simptomov daljši kot pri bolnikih, ki so jemali placebo.
Patients who also have major depression should start with 60 mg once a day. 
Pri bolnikih tako z generalizirano anksiozno motnjo kot velikimi depresivnimi motnjami naj bo začetni odmerek 60 mg enkrat na dan.
How is Duloxetine Lilly used? 
Kako se zdravilo Duloxetine Lilly uporablja?
How does Duloxetine Lilly work? 
Kako zdravilo Duloxetine Lilly deluje?
It is not intended to provide practical advice on how to use Duloxetine Lilly. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Duloxetine Lilly was shown to be more effective than placebo at treating the disorder and preventing symptoms returning. 
Rezultati so pokazali, da je zdravilo Duloxetine Lilly pri zdravljenju bolezni in preprečevanju ponovnega pojava simptomov učinkovitejše od placeba.
The patients were treated for eight weeks. 
Bolnike so zdravili osem tednov.
'Essential' means that the hypertension has no obvious cause. 
Izraz „esencialna“ pomeni, da za hipertenzijo ni očitnega vzroka.
It is available as tablets in the following strengths: 150 /5/12.5 mg; 300/5/12.5 mg; 300/5/25 mg; 300/10/12.5 mg; and 300/10/25 mg. 
Na voljo je v obliki tablet naslednjih jakosti: 150/5/12,5 mg, 300/5/12,5 mg, 300/5/25 mg, 300/10/12,5 mg in 300/10/25 mg.
The European Commission granted a marketing authorisation valid throughout the European Union for Rasitrio on 22 November 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Rasitrio, veljavno po vsej Evropski uniji, odobrila dne 22. novembra 2011.
The tablet should be swallowed whole with water. 
Tableto je treba pogoltniti celo z vodo.
The full EPAR for Rasitrio can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Rasitrio je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter. 
Zavira posebne kanalčke na površini celic, imenovane kalcijevi kanalčki, skozi katere običajno vstopajo kalcijevi ioni.
The patient should take one tablet once a day with a light meal, preferably at the same time each day. 
Bolnik mora zdravilo jemati z lahkim obrokom enkrat na dan, najbolje vsak dan ob istem času.
This is a summary of the European public assessment report (EPAR) for Rasitrio. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Rasitrio.
It should not be taken together with grapefruit juice. 
Zdravilo se ne sme jemati skupaj z grenivkinim sokom.
The Committee therefore decided that Rasitrio's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zato zaključil, da so koristi zdravila Rasitrio večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Aliskiren is a renin inhibitor. 
Aliskiren je zaviralec renina.
For more information about treatment with Rasitrio, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Rasitrio preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rasitrio. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Rasitrio, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The CHMP noted that taking the three active substances in one tablet, as opposed to taking separate tablets, may lead to better compliance with treatment. 
CHMP je ugotovil, da lahko jemanje treh zdravilnih učinkovin v eni tableti v primerjavi z jemanjem posameznih tablet izboljša sodelovanje bolnikov pri zdravljenju.
What benefit has Rasitrio shown during the studies? 
Kakšne koristi je zdravilo Rasitrio izkazalo med študijami?
The main measure of effectiveness was the reduction in the average systolic blood pressure (blood pressure when the heart is contracting) measured when the patients were seated. 
Glavno merilo učinkovitosti je bilo znižanje povprečnega sistoličnega krvnega tlaka (krvnega tlaka, merjenega pri krčenju srca), izmerjenega pri bolniku v sedečem položaju.
After eight weeks, patients treated with Rasitrio had an average reduction in sitting systolic blood pressure of 37.4 mmHg. 
Po osmih tednih zdravljenja z zdravilom Rasitrio se je sistolični krvni tlak pri bolniku, merjen v sedečem položaju, v povprečju znižal za 37,4 mmHg.
Amlodipine is a calcium channel blocker. 
Amlodipin je zaviralec kalcijevih kanalčkov.
The company also presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets. 
Družba je predstavila tudi študije, ki so pokazale, da se tableta, ki vsebuje vse tri zdravilne učinkovine, v telesu absorbira enako kot posamezne tablete.
What is the risk associated with Rasitrio? 
Kakšna tveganja so povezana z zdravilom Rasitrio?
The most frequent adverse reactions for Rasitrio are hypotension and dizziness. 
Najpogostejša neželena učinka zdravila Rasitrio sta hipotenzija in omotica.
EPAR summary for the public aliskiren / amlodipine / hydrochlorothiazide 
Povzetek EPAR za javnost aliskiren/amlodipin/hidroklorotiazid
When calcium ions enter the cells in the muscles of blood vessel walls, this causes contraction. 
Ko kalcijevi ioni vstopijo v celice mišic v žilnih stenah, se začnejo žile krčiti.
Patients should be switched to the fixed combination tablet of Rasitrio that contains the same component doses as previously used individually. 
Bolniki morajo preiti na tablete zdravila Rasitrio s fiksno kombinacijo, ki vsebuje enake odmerke zdravilnih učinkovin kot predhodno uporabljeni posamezni odmerki.
This causes vasodilation (widening of the blood vessels), so that the blood pressure drops. 
To povzroči vazodilatacijo (razširjenje krvnih žil), zaradi česar se krvni tlak zniža.
The combination of these three active substances reduces blood pressure more than either medicine acting alone. 
Kombinacija teh treh zdravilnih učinkovin znižuje krvni tlak bolj kot vsako posamezno zdravilo posebej.
Other information about Rasitrio 
Druge informacije o zdravilu Rasitrio:
Rasitrio must not be used in people who are hypersensitive (allergic) to aliskiren, amlodipine, or hydrochlorothiazide, to any of the other ingredients of the medicine or other substances derived from dihydropyridine (a group that includes amlodipine) or sulphonamide (includes hydrochlorothiazide). 
Zdravila Rasitrio ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) aliskiren, amlodipin ali hidroklorotiazid ali na katero koli drugo sestavino zdravila ali druge snovi, pridobljene iz dihidropiridina (skupine, ki vključuje amlodipin) ali sulfonamida (vključuje hidroklorotiazid).
It works by increasing urine production, reducing the volume of fluid in the blood and lowering the blood pressure. 
Deluje tako, da poveča tvorjenje urina, zaradi česar se zmanjša količina tekočine v krvi in zniža krvni tlak.
For the full list of all side effects reported with Rasitrio, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rasitrio, glejte navodilo za uporabo.
The main study showed a greater reduction in blood pressure with Rasitrio than with combinations of two active substances. 
Glavna študija je pokazala večje znižanje krvnega tlaka pri jemanju zdravila Rasitrio v primerjavi s kombinacijo dveh zdravilnih učinkovin.
Studies also showed that the active substances in Rasitrio are absorbed in the body in the same way as the active substances when given as separate tablets. 
Študije so tudi pokazale, da se zdravilne učinkovine iz zdravila Rasitrio v telo absorbirajo enako kot zdravilne učinkovine, ki se jemljejo kot posamezne tablete.
By blocking the activity of renin, levels of both, angiotensin I and angiotensin II, fall. 
Z zaviranjem delovanja renina se zniža raven angiotenzina I in angiotenzina II.
Rasitrio is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose. 
Zdravilo Rasitrio se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih je krvni tlak že ustrezno uravnan z uporabo kombinacije aliskirena, amlodipina in hidroklorotiazida, ki se jemljejo sočasno v enakih odmerkih.
By reducing the flow of calcium into the cells, amlodipine prevents the blood vessel walls from contracting, thus lowering the blood pressure. 
Amlodipin z zmanjševanjem pretoka kalcija v celice preprečuje krčenje žilnih sten in tako znižuje krvni tlak.
In a main study in 1,191 patients with moderate or severe hypertension, Rasitrio combinations containing the three active substances were compared with combinations containing only two active substances: aliskiren plus amlodipine, amlodipine plus hydrochlorothiazide, and aliskiren plus hydrochlorothiazide. 
V glavni študiji, v kateri je bilo vključenih 1 191 bolnikov z zmerno ali hudo hipertenzijo, so primerjali zdravilo Rasitrio, ki je vsebovalo kombinacijo treh zdravilnih učinkovin, s kombinacijo, ki je vsebovala samo dve zdravilni učinkovini: aliskiren z amlodipinom, amlodipin s hidroklorotiazidom in aliskiren s hidroklorotiazidom.
Why has Rasitrio been approved? 
Zakaj je bilo zdravilo Rasitrio odobreno?
The strength of the Rasitrio tablet that the patient takes depends on the doses of aliskiren, amlodipine and hydrochlorothiazide that they received previously. 
Jakost tablet Rasitrio, ki jih bolnik jemlje, je odvisna od odmerka aliskirena, amlodipina in hidroklorotiazida, ki ga je bolnik predhodno jemal.
The Rasitrio combination was more effective than the double combinations at reducing systolic blood pressure. 
Kombinacija zdravila Rasitrio je bila pri zniževanju sistoličnega krvnega tlaka učinkovitejša od kombinacije z dvema zdravilnima učinkovinama.
Rasitrio is a medicine that contains the active substances aliskiren, amlodipine and hydrochlorothiazide. 
Rasitrio je zdravilo, ki vsebuje zdravilne učinkovine aliskiren, amlodipin in hidroklorotiazid.
Reductions of 28.2 mmHg, 30.6 mmHg and 30.8 mmHg were seen for aliskiren plus hydrochlorothiazide, aliskiren plus amlodipine and amlodipine plus hydrochlorothiazide respectively. 
Pri jemanju aliskirena v kombinaciji s hidroklorotiazidom se je znižal za 28,2 mmHg, pri jemanju aliskirena v kombinaciji z amlodipinom za 30,6 mmHg, pri jemanju amlodipina v kombinaciji s hidroklorotiazidom pa za 30,8 mmHg.
What is Rasitrio used for? 
Za kaj se zdravilo Rasitrio uporablja?
Angiotensin I is converted into the hormone angiotensin II, which is a powerful vasoconstrictor (a substance that narrows blood vessels). 
Zavira dejavnost encima, imenovanega renin, ki v telesu sodeluje pri tvorjenju spojine, imenovane angiotenzin I. Angiotenzin I se pretvori v hormon angiotenzin II, ki deluje kot močan vazokonstriktor (učinkovina, ki oži žile).
How has Rasitrio been studied? 
Kako je bilo zdravilo Rasitrio raziskano?
How does Rasitrio work? 
Kako zdravilo Rasitrio deluje?
How is Rasitrio used? 
Kako se zdravilo Rasitrio uporablja?
Rasitrio contains three active substances, aliskiren, amlodipine, and hydrochlorothiazide. 
Zdravilo Rasitrio vsebuje tri zdravilne učinkovine: aliskiren, amlodipin in hidroklorotiazid.
What is Rasitrio? 
Kaj je zdravilo Rasitrio?
London, 26 June 2008 Doc. 
London, 26. junij 2008 Dok.
The virus used in the vaccine was first inactivated (killed) so that it does not cause any disease. 
Virus, ki se uporablja pri tem cepivu, je najprej inaktiviran (ubit), tako da ne more povzročati nobenih obolenj.
Aflunov also contains an ‘adjuvant' (a compound containing oil), which is expected to stimulate a better response. 
Aflunov vsebuje tudi adjuvant (sestavino, ki vsebuje olje), ki naj bi spodbujalo boljšo odzivnost.
On 13 June 2008, Novartis Vaccines and Diagnostics S.r.l. 
Družba Novartis Vaccines and Diagnostics S.r.l.
This helps to protect against the disease. 
To pomaga zaščititi telo pred boleznijo.
Consequently, the study results could not be considered reliable and could not be used for the evaluation of the vaccine. 
Posledično rezultati študije niso bili ocenjeni kot zanesljivi in jih ni bilo mogoče uporabiti pri ocenjevanju cepiva.
The main clinical study of Aflunov involved over 4,000 adults. 
Glavna klinična študija zdravila Aflunov je vključevala več kot 4000 odraslih.
Following the CHMP's opinion, it usually takes around two months for the European Commission to grant a licence. 
Potem ko CHMP izda svoje mnenje, navadno traja približno dva meseca, preden Evropska komisija dovoljenje odobri.
This is a special type of vaccine that is intended to protect against a strain of flu that may cause a future pandemic. 
To je posebna vrsta cepiva, namenjenega zaščiti pred sevom gripe, ki lahko povzroča pandemijo v prihodnosti.
As a result, the size of the clinical database for the assessment of the vaccine's safety was not sufficient to fulfil the requirements of the EMEA's guidelines on prepandemic vaccines. 
Tako velikost klinične podatkovne baze za ocenjevanje varnosti cepiva ni bila zadostna za izpolnitev določil smernic agencije EMEA o predpandemičnih cepivih.
The effects of Aflunov were first tested in experimental models before being studied in humans. 
Učinki zdravila Aflunov so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Then, the outer membranes that contain the ‘surface antigens' (proteins on the outer membrane of the virus that the body recognises as foreign) were extracted and purified before being included in the vaccine. 
Nato so bile zunanje membrane, ki vsebujejo površinske antigene (beljakovine na zunanji membrani virusa, ki ga telo prepoznava kot tujek), izločene in prečiščene, preden so bile ponovno dodane v cepivo.
It consists of a suspension for injection that contains some parts (outer membranes) of the influenza (flu) virus strain called A/VietNam/1194/2004. 
Sestavljeno je iz suspenzije za injiciranje, ki vsebuje nekatere dele (zunanje membrane) seva virusa influence (gripa), imenovanega A/VietNam/1194/2004.
An inspection of some of the study sites showed that the study had not been conducted in compliance with ‘good clinical practice' (GCP). 
Pregled nekaterih točk študije je namreč razkril, da študija ni bila izvedena v skladu z dobro klinično prakso.